Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SKYEY - SkyePharma PLC -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (15)	4/6/1999 11:59:00 PM
From: Dr. John M. de Castro	Respond to of 56

Rudy, I finally got time to listen to the recording of the conference call. I agree with your assessment except for the following: >"SkyePharma expects to file DepoCyt in Europe (for neoplastic meningitis) in late summer. Approval is anticipated 12 months later." My understanding from the call was that the EU approval process would only take 4 months and not 12 from the date of filing. There was a very upbeat tone to the call. One interesting point that Ashton made was that he was viewing DepoCyt as a annuity. Although the market is not large, there is and will be no competition. So, DepoCyt will continue as the treatment of choice indefinitely. So, he sees DepoCyt, not as a hare but a tortoise, providing a consistent revenue, building over the next few years to $50 million or so, that will accrue to the company for years to come. This could form part of a reliable cash flow base to support the R&D efforts to produce some hares. I like business strategies that combine cash cows with riskier ventures. This allows for creativity and risk without having to bet the company on success. John de C